Finanzen von Abivax SA (ABVX)ABVXAbivax SA

In the context of the broader market, ABVX competes directly with industry leaders such as BHC and CRON. With a market capitalization of $7.52B, it holds a leading position in the sector. When comparing efficiency, ABVX's gross margin of N/A stands against BHC's 65.04% and CRON's 53.69%. Such benchmarking helps identify whether Abivax SA is trading at a premium or discount relative to its financial performance.

Abivax has a negative P/E ratio of -14.36 and a forward P/E of 0, indicating a lack of earnings. The price-to-sales ratio is extremely high at 1664.85, suggesting overvaluation based on current sales.